Core Viewpoint - Laureate Education, Inc. reported strong financial performance for 2025, with significant revenue growth and margin expansion, while also increasing its share repurchase authorization by $150 million to a total of $400 million [1][4][13]. Financial Performance Highlights Fourth Quarter 2025 - Reported revenue was $541.4 million, an increase of $118.0 million or 28% compared to Q4 2024; organic constant currency revenue increased by 16% [5][6]. - Operating income rose to $179.5 million from $124.2 million in Q4 2024, an increase of $55.3 million [5][6]. - Net income for Q4 2025 was $171.5 million, up from $93.6 million in Q4 2024, reflecting an increase of $77.9 million [5][6]. - Basic and diluted earnings per share were $1.18 and $1.17, respectively [5][6]. Year Ended December 31, 2025 - Total revenue for the year was $1,701.9 million, a 9% increase from $1,566.6 million in 2024; organic constant currency revenue increased by 8% [9][10]. - Operating income for 2025 was $431.1 million, compared to $374.0 million in 2024 [9][10]. - Net income decreased to $283.8 million from $296.4 million in 2024, primarily due to foreign currency exchange rate impacts [9][10]. - Adjusted EBITDA for 2025 was $518.9 million, up from $450.1 million in 2024 [10]. Enrollment Metrics - New enrollments for FY 2025 increased by 8% compared to FY 2024, with total enrollments up by 5% [8][9]. - In Peru, new enrollments increased by 13% and total enrollments by 7%; in Mexico, new enrollments rose by 5% and total enrollments by 4% [8]. Balance Sheet and Cash Flow - As of December 31, 2025, Laureate had $146.7 million in cash and cash equivalents, with gross debt of $129.1 million, resulting in net cash of $17.6 million [11]. - The company repurchased approximately $217 million of its common stock during 2025, with $31 million remaining under the previous repurchase authorization [12][13]. Outlook for 2026 - For FY 2026, Laureate expects total enrollments to be between 516,000 and 521,000, reflecting a growth of 4%-5% compared to 2025 [14]. - Revenue is projected to be in the range of $1,890 million to $1,905 million, indicating growth of 11%-12% on a reported basis and 6%-7% on an organic constant currency basis [14].

MONTRÉAL, Feb. 19, 2026 (GLOBE NEWSWIRE) -- Bombardier Inc. (“Bombardier”) today announced that it has issued a notice of redemption (the “Notice of Redemption”) for all of its remaining outstanding 6.000% Senior Notes due 2028, in an aggregate principal amount of US$250,000,000 (the “2028 Notes”). As set forth in the Notice of Redemption, the redemption date is March 6, 2026, and the redemption price for the 2028 Notes is 100% of the principal amount redeemed, plus accrued and unpaid interest. This debt re ...

Financial Performance - For Q4 2025, Navios Partners reported a net income of $117.3 million and EBITDA of $224.8 million, with earnings per common unit at $3.99. For the full year 2025, net income was $285.3 million and EBITDA was $744.6 million, with earnings per common unit at $9.59 [2][5][19]. - Revenue for Q4 2025 was $365.6 million, a 10% increase from $332.5 million in Q4 2024. For the full year, revenue was $1,344.1 million, a slight increase of 0.7% from $1,334.1 million in 2024 [21][26]. Distribution Policy - The company announced a 20% increase in its distribution policy to $0.24 per unit annually, effective from Q1 2026, translating to $0.06 per unit quarterly [2][6][5]. Fleet and Operations - As of February 12, 2026, Navios Partners had repurchased 1,603,713 common units for approximately $72.9 million, with a total of 28,580,675 common units outstanding [3]. - The fleet consists of 67 dry bulk vessels, 51 containerships, and 53 tankers, including 16 newbuilding tankers expected to be delivered through the first half of 2028 [17]. - The company has contracted revenue of $3.8 billion through 2037, with $261 million in new long-term charters expected to generate additional revenue [10][11]. Vessel Transactions - In Q4 2025, Navios Partners acquired two Japanese newbuilding capesize vessels for $134.3 million and agreed to sell two VLCC tankers for $136.5 million [7][8]. - A newbuilding aframax/LR2 tanker was delivered in February 2026, chartered out at a rate of $27,431 net per day for approximately five years [9]. Financial Position - As of December 31, 2025, total assets were $5.93 billion, with total liabilities at $2.59 billion and total partners' capital at $3.34 billion [41]. - Cash and cash equivalents increased to $413.5 million from $312.1 million in 2024 [41]. Market Environment - The company noted that geopolitical tensions and new trade agreements are reshaping trade routes, impacting costs and transit times. This evolving landscape is seen as an opportunity for Navios Partners to leverage its diversified fleet and risk management culture [2].

Core Insights - Kane Biotech Inc. has signed non-exclusive distribution and sales agreements for its revyve Antimicrobial Wound Gel product line with Patient Care Medical and Life Biologics, enhancing its market presence in the U.S. [1][2] Group 1: Distribution Agreements - The agreements with Patient Care Medical and Life Biologics will expand Kane Biotech's presence in targeted sales channels and geographic markets, with Life Biologics distributing nationally and Patient Care Medical focusing on Louisiana, Mississippi, and the Gulf Coast [2][3] - Initial shipments of the revyve product line are being prepared for the near term [2] Group 2: Company Strategy and Product Information - Expanding the U.S. distribution network is a key priority for Kane Biotech, supporting its near-term commercialization objectives [3] - Kane Biotech is focused on developing novel wound care treatments that disrupt biofilms, which contribute to antibiotic resistance in wounds, with its revyve product line addressing both biofilms and wound bacteria [3] - The revyve Antimicrobial Wound Gel and its variants are U.S. FDA 510(k) cleared and Health Canada approved, indicating regulatory compliance and market readiness [3]

Core Viewpoint - Jiuzi Holdings, Inc. is actively pursuing an expansion of its private placement offering following a successful $60 million initial financing round, aiming to raise up to $100 million to enhance its Digital Asset Treasury (DAT) strategy [1][2]. Group 1: Financing and Investment Interest - The company has completed an initial $60 million private placement and is in discussions to raise an additional $100 million at a minimum price of $2 per share [1][2]. - Institutional investors from the initial round have shown interest in further subscriptions, while new investors are conducting due diligence to participate in the expanded financing [2]. Group 2: Strategic Objectives of Expanded Financing - The new funds will enhance the company's digital asset reserves, improving the treasury's capacity and flexibility under varying market conditions [3]. - The company plans to optimize its asset allocation structure by leveraging partner institutions' expertise in risk pricing and on-chain allocation [3]. - The financing will accelerate the deployment of on-chain applications, focusing on cross-chain asset management and financial applications [3]. - The company aims to improve its treasury governance framework by developing standards for digital asset admission, audit procedures, and risk management [3]. Group 3: Management's Perspective - Management emphasizes that the expansion plan reflects strong recognition from institutional investors regarding the company's strategic direction and governance capabilities [4]. - The company intends to maintain an open and collaborative approach with partners to enhance treasury structure and governance processes [4].

Core Insights - Appian reported a fourth quarter cloud subscriptions revenue increase of 18% year-over-year to $117.0 million and a full year increase of 19% to $437.4 million [1][6]. Fourth Quarter 2025 Financial Highlights - Total subscriptions revenue rose 19% year-over-year to $162.3 million, with professional services revenue increasing by 36% to $40.6 million [6]. - Total revenue for the fourth quarter was $202.9 million, reflecting a 22% increase compared to the same quarter in 2024 [6]. - Cloud net annualized recurring revenue (ARR) expansion was 114% as of December 31, 2025 [6]. - GAAP operating loss was $(0.7) million, while non-GAAP operating income was $17.4 million [6]. - GAAP net loss was $(5.1) million, with a net loss per share of $(0.07) [6]. - Adjusted EBITDA for the quarter was $19.7 million [6]. Full Year 2025 Financial Highlights - Full year cloud subscriptions revenue reached $437.4 million, up 19% from 2024 [6]. - Total subscriptions revenue increased 18% year-over-year to $576.5 million [6]. - Professional services revenue for the year was $150.5 million, compared to $126.5 million in 2024 [6]. - Total revenue for the year was $726.9 million, an 18% increase from 2024 [6]. - GAAP operating income was $0.6 million, a significant improvement from a $(60.9) million loss in 2024 [6]. - GAAP net income was $1.2 million, compared to a $(92.3) million loss in 2024 [6]. - Adjusted EBITDA for the year was $76.8 million [6]. Business Highlights - Appian secured an enterprise agreement with the US Army to support AI-powered transformation efforts [6]. - The company launched new AI capabilities aimed at automating complex workflows and accelerating application modernization [6]. - Appian recognized the 2025 Public Sector Partner Award winners [6]. - The New Zealand Police implemented Appian for case processing [6]. Financial Outlook - For the first quarter of 2026, cloud subscriptions revenue is expected to be between $119.0 million and $121.0 million, representing year-over-year growth of 19% to 21% [12]. - Total revenue for the first quarter is projected to be between $189.0 million and $193.0 million, indicating a year-over-year increase of 14% to 16% [12]. - For the full year 2026, cloud subscriptions revenue is anticipated to be between $502.0 million and $510.0 million, reflecting year-over-year growth of 15% to 17% [12].

Core Insights - InterCure reported preliminary estimated revenue of NIS 265 million for 2025, marking an 11% increase compared to 2024, with nearly 20% revenue growth in the second half of 2025 compared to the same period in the previous year [1][5][6] - The company achieved positive Adjusted EBITDA for the twelfth consecutive half-year, indicating consistent operational profitability [1][5][6] - Significant revenue generation from the German market began in the second half of 2025, contributing to the company's global expansion strategy [1][6] Financial Performance - Estimated annual revenue for 2025 is NIS 265 million, with approximately NIS 135 million generated in the second half [5] - Cash on hand as of December 31, 2025, was NIS 43 million [5] - The company resumed production and sales from the Nir Oz facility after disruptions due to the October 7, 2023 attack [5] Strategic Developments - InterCure launched over 70 new GMP SKUs in 2025, establishing category-leading positions in premium medical products [5] - The company entered into a share purchase agreement to acquire Botanico Ltd., expected to enhance access to premium U.S. genetics and cultivation technologies, with anticipated revenues of over NIS 30 million in the second half of 2026 [5][6] - A strategic investment and collaboration agreement with Cannasoul R&D Ltd. was established, acquiring a 28% stake with an option to increase to 51% within two years, enhancing research and pharmaceutical capabilities [5][6] Regulatory and Market Positioning - The company is closely monitoring regulatory developments in the U.S. regarding cannabis regulations and believes it is well-positioned to benefit from evolving market conditions [5][6] - InterCure's vertically integrated model and international partnerships are expected to drive long-term value for patients and shareholders [6][7]

Core Viewpoint - Advantage Solutions Inc. is set to release its financial results for the fourth quarter and full year on March 3, 2026, at 7 a.m. EDT, followed by a conference call at 8:30 a.m. EDT [1] Group 1: Financial Results Announcement - The financial results will be announced on March 3, 2026, at 7 a.m. EDT [1] - A conference call will follow the announcement at 8:30 a.m. EDT on the same day [1] Group 2: Conference Call Access - U.S. callers can access the conference call by dialing 1-800-715-9871, while international callers can dial 1-646-307-1963 [2] - The conference ID for the call is 5720569 [2] - A replay of the call will be available approximately three hours after it concludes, accessible via 1-800-770-2030 for U.S. callers and 1-609-800-9909 for international callers, with the playback ID being 5720569 [2] Group 3: Webcast Information - Investors can also listen to a simultaneous conference call webcast by visiting the Investor Relations section of the Advantage Solutions website [3] - The online replay will be available for a limited time shortly after the call [3] Group 4: Company Overview - Advantage Solutions is the leading omnichannel retail solutions agency in North America, positioned at the intersection of consumer-packaged goods (CPG) brands and retailers [4] - The company utilizes data- and technology-powered services to help brands and retailers generate demand and distribute products effectively [4] - Advantage Solutions focuses on enhancing in-store and online experiences, optimizing assortment and merchandising, and accelerating e-commerce capabilities [4] - The company has a presence throughout North America and strategic investments in select international markets [4]

Core Insights - Regeneron Pharmaceuticals has announced that the FDA has accepted the Biologics License Application for garetosmab, which could become the first treatment for adults with fibrodysplasia ossificans progressiva (FOP) [1][5] Group 1: Disease Overview - FOP is an ultra-rare genetic disorder characterized by abnormal bone formation that leads to significant disability, with approximately 900 diagnosed cases worldwide [2] - The median age of survival for individuals with FOP is around 56 years, and most patients are wheelchair-bound by the age of 30 [2] Group 2: Clinical Trial and Efficacy - The BLA for garetosmab is supported by data from the Phase 3 OPTIMA trial, which showed that both doses of garetosmab (3 mg/kg and 10 mg/kg) significantly reduced the number and volume of new heterotopic ossification (HO) lesions compared to placebo [3] - Specifically, the 3 mg/kg dose resulted in a 94% reduction in new lesions (1 lesion vs. 19 lesions; p=0.0274), while the 10 mg/kg dose showed a 90% reduction (2 lesions vs. 19 lesions; p=0.0260) [3] - A post-hoc analysis indicated both doses achieved over 99% reduction in mean total volume of new HO lesions compared to placebo [3] Group 3: Safety Profile - Among the 63 participants in the OPTIMA trial, serious treatment-emergent adverse events were reported in 1 patient on the 3 mg/kg dose, 2 patients on the 10 mg/kg dose, and 2 patients on placebo [4] - Common adverse reactions (≥30% incidence) included epistaxis, increased hair growth, abscess, and acne [4] Group 4: Regulatory Status - Garetosmab has received Priority Review status from the FDA, indicating its potential to significantly improve treatment for serious conditions [5] - The drug has also been granted Fast Track and Orphan Drug Designations by the FDA, as well as Orphan Designation in the European Union [5] Group 5: Future Developments - A Phase 3 trial of garetosmab in adolescents and children with FOP, named OPTIMA 2, is planned to begin later this year [10]

Sales for the quarter increased 7.7 percent. Organic sales increased 1.6 percent, acquisitions increased sales 2.3 percent and foreign currency translation increased sales 3.8 percent.Diluted EPS increased 21.7 percent to $1.01 in the second quarter of fiscal 2026 compared to $0.83 in the same quarter of the prior year. Adjusted Diluted EPS* increased 9.0 percent to $1.09 in the second quarter of fiscal 2026 compared to $1.00 in the same quarter of the prior year.Net cash provided by operating activities in ...